In vivo regulation of serotonin 5-HT(2A) receptors in rat brain by subchronic administration of σ receptor ligand NE-100

Life Sciences

Volumn 60, Issue 24, 1997, Pages 2245-2254

  Hashimoto, Kenji ^a,b,c   Narita, Natsuko ^a   Tomitaka, Shin Ichiro ^a   Iyo, Masaomi ^b   Minabe, Yoshio ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^c Yoshitomi Pharmaceutical Industries Ltd   (Japan)

Author keywords

antipsychotic drug; brain; in vivo binding; in vivo regulation; NE 100; serotonin 5 HT(2A) rcceptors; sigma receptors

Indexed keywords

2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL] N,N DIPROPYLETHYLAMINE; FANANSERIN; NEUROLEPTIC AGENT; SEROTONIN 2A RECEPTOR; SIGMA OPIATE RECEPTOR; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DRUG RECEPTOR BINDING; FRONTAL CORTEX; HIPPOCAMPUS; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; OCCIPITAL CORTEX; PARIETAL LOBE; RAT; SCHIZOPHRENIA;

ANIMALS; ANISOLES; ANTIPSYCHOTIC AGENTS; BRAIN; CYCLIC S-OXIDES; KINETICS; LIGANDS; MALE; NAPHTHALENES; PROPYLAMINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; RECEPTORS, SIGMA; SEROTONIN ANTAGONISTS;

EID: 0030991880     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(97)00239-7     Document Type: Article

References (41)

1. W.R. MARTIN, C.G. EADES, J.A. THOMPSON, R.E. HUPPLER and P.E. GILBERT, J. Pharmacol. Exp. Ther. 197 517-532 (1976).
2. S.I. DEUTSCH, A. WEIZMAN, M.E. GOLDMAN and J.M. MORIHISA, Clin. Neuropharmacol. 11 105-119 (1988).
3. S.H. SNYDER and B.L. LARGENT, J. Neuropsychiatry 1 7-15 (1989).
4. Y. ITZHAK and I. STEIN, Life Sci. 47 1073-1081 (1990).
5. J.M. WALKER, W.D. BOWEN, F.O. WALKER, R.R. MATSUMOTO, B. DE COSTA and K.C. RICE, Pharmacol. Rev. 42 355-402 (1990).
6. T.-P. SU, Eur. J. Biochem. 200 633-642 (1991).
7. T.-P. SU, Crit. Rev. Neurobiol. 7 187-203 (1993).
8. T.-P. SU, J. Pharmacol. Exp. Ther. 223 284-290 (1982).
9. S.W. TAM and L. COOK, Proc. Natl. Acad. Sci. USA 81 5618-5621 (1984).
10. B.L. LARGENT, H. WIKSTRÖM, A.M. SNOWMAN and S.H. SNYDER, Eur. J. Pharmacol. 155 345-347 (1988).
11. R.M. FERRIS, F.L.M. TANG, K.-J. CHANG and A. RUSSELL, Life Sci. 38 2329-2337 (1986).
12. D.P. TAYLOR and J. DEKLEVA, Drug Dev. Res. 11 65-70 (1987).
13. F.J. HOCK, H. KRUSE, H.J. GERHARDS and E. KONZ, Drug Dev. Res. 6301-311 (1985).
14. L. COOK, S.W. TAM and K.W. ROHRBACH, J. Pharmacol. Exp. Ther. 263 1159-1166 (1992).
15. S.W. TAM, G.F. STEINFELS, P.J. GILLIGAN, W.K. SCHMIDT and L. COOK, J. Pharmacol. Exp. Ther. 263 1167-1174 (1992)
16. E.W. KARBON, M.E. ABREU, R.H. ERICKSON, C. KAISER, K.J. NATALIE, D.B. CLISSOLD, S. BOROSKY, M. BAILEY, L.A. MARTIN, M.J. PONTECORVO, E.S.J. ENNA and J.W. FERKANY, J. Pharmacol. Exp. Ther. 265 866-875 (1993).
17. D.B. CLISSOLD, M.J. PONTECORVO, M.E. JONES, M.E. ABREU, E.W. KARBON, R.H. ERICKSON, K.J. NATALIE, S. BOROSKY, JR., T. HARTMAN, R.S. MANSBACH, R.L. BALSTER, J.W. FERKANY and S.J. ENNA, J. Pharmacol. Exp. Ther. 265 876-886 (1993).
18. A.D. WEISSMAN, M.F. CASANOVA, J.E. KLEIMAN, E.D. LONDON and E.B. DE SOUZA, Biol. Psychiatry 29 41-54 (1991).
19. H. SHIBUYA, H. MORI and M. TORU, Neurochem. Res. 17 983-990 (1992).
20. M.D.C. SIMPTON, P. SLATER, M.C. ROYSTON and J.F.W. DEAKIN, Schizophrenia Res. 6 41-48 (1992).
21. M. HANNER, F.F. MOEBIUS, A. FLANDORFER, H.-G. KNAUS, J. STRIESSNIG, E. KEMPNER and H. GLOSSMANN, Proc. Natl. Acad. Sci. USA 93 8072-8077 (1996).
22. E. ZIFA and G. PILLION, Pharmacol. Rev. 44 401-458 (1992).
23. R.W. FULLER, J. Clin. Psychiatry 53 36-45 (1992).
24. J.M. KANE, New Eng. J. Med. 334 34-41 (1996).
25. B.J. KINON and J.A. LIEBERMAN, Psychopharmacol. 124 2-34 (1996).
26. H.Y. MELTZER, M.A. LEE and R. RANJAN, Acta. Psychiatr. Scand. 90 95-101 (1994).
27. A. BREIER, Schizophrenia Res. 14 187-202 (1995).
28. S. KAPUR, Psychopharmacol. 124 35-39 (1996).
29. T. MITA, S. HANADA, N. NISHINO, T. KLINO, H. NAKAI, T. YAMADORI, Y. MIZOI and C. TANAKA, Biol. Psychiatry 21 1407-1414 (1986).
30. M. LARUELLE, A. ABI-DARGHAM, M.F. CASANOVA, R. TOTI, D.R. WEIBERGER and J.E. KLEINMAN, Arch. Gen. Psychiatry 50 810-818 (1993).
31. S. OKUYAMA, Y. IMAGAWA, S. OGAWA, H. ARAKI, A. AJIMA, M. TANAKA, M. MURAMATU, A. NAKAZATO, K. YAMAGUCHI, M. YOSHIDA and S. OTOMO, Life Sci. 53 PL 285-290 (1993).
32. S. OKUYAMA, Y. IMAGAWA, T. SAKAGAWA, A. NAKAZATO, K. YAMAGUCHI, M. KATOH, S. YAMADA, H. ARAKI AND S. OTOMO, Life Sci 55 PL 133-138 (1994).
33. D.C. JAVITT and S.R. ZUKIN, Am. J. Psychiatry 148 1301-1308 (1991).
34. K. HASHIMOTO and E.D. LONDON, Eur. J. Pharmacol. 236 159-163 (1993).
35. K. HASHIMOTO, U. SCHEFFEL and E.D. LONDON, Synapse 20 85-90 (1995).
36. N. NARITA, K. HASHIMOTO, M. IYO, Y. MINABE and K. YAMAZAKI, Eur J. Pharmacol. 293 277-280 (1995).
37. N. NARITA, K. HASHIMOTO, S. TOMITAKA, Y. MINABE and K. YAMAZAKI, Abstr. for Neurosci. 21 443.13 (1995).
38. Y. SHIRAYAMA, N. NISHIKAWA, A. UMINO and K. TAKAHASHI, Eur. J. Pharmacol. 237 117-126 (1993).
39. A. DOBLE, D. GIRDLESTONE, O. PIOT, D. ALLAM, J. BETSCHART, A BOIREAU, A. DUPUY, C. GUEREMY, J. MENAGER, J.L. ZUNDEL and JC BLANCHARD, Bri. J. Pharmacol. 105 27-36 (1992).
40. C. FAJOLLES, A. BOIREAU, M. PONCHANT and P.M. LADURON, Eur. J. Pharmacol. 216 53-57 (1992).
41. S. CHAKI, M. TANAKA, M. MURAMATSU and S. OTOMO, Eur. J. Pharmacol. 251 R1-R2 (1994).